Latest Amylyx Pharmaceuticals News & Updates

See the latest news and media coverage for Amylyx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amylyx Pharmaceuticals (Amylyx)

Clinical-stage biopharmaceutical company developing therapies for serious diseases

Last updated Today

Latest news about Amylyx Pharmaceuticals (Amylyx)

In short: Amylyx announced positive Phase 3 results for avexitide and raised $500 million through an upsized public stock offering.

August 18 Amylyx

The company intends to use proceeds for avexitide manufacturing, R&D, and working capital. An option for additional shares is available.

August 17 Amylyx

The update arrives August 18 during a live call analyzing avexitide efficacy for post-bariatric hypoglycemia.

August 6 Amylyx

Net loss was $43.4 million; cash runway expected into 2028. Topline LUCIDITY data expected late August or early September 2026.

June 23 Amylyx

The LUMINA trial showed no drug-related serious adverse events in Cohort 1, supporting further study.

September 7 Gelbe Liste

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor...

Never miss news about Amylyx

Track Amylyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Amylyx and other trending companies.